Eli Lilly released phase 2b trial results comparing the investigational eloralintide-tirzepatide combo with tirzepatide 15 mg alone in patients with T2D and obesity.
|Articles|July 21, 2003
Pharmacist review of drug regimens reduces polypharmacy
Clinical pharmacists at Henry Ford hospital have been reviewing patients in the HAP plan to avert polypharmacy.
Advertisement
Advertisement
Related to this article
To guide public health and vaccination strategies, researchers assessed a variety of factors regarding community-acquired pneumonia and its causes.
Highlighting the clinical impact of the pharmacy profession, we caught up with pharmacists of various types to get their perspectives on the evolution of pharmacy.
A newly erected Women’s Health Division within NIH will work in tandem with the Office of Research on Women’s Health.
Rita King, CEO of MethodSense, provides her expertise on the integration of AI in medical devices and key developments for pharmacists as the technology evolves.
Harini Bupathi, Esq, explains why pharmacies need to continue prioritizing PBM relationships despite rapid legislative change.
Researchers assessed the extent of which vaccine fatigue translates to reduced engagement and adherence among patients.
Brianne Porter, PharmD, MS, explores how pharmacists can deliver care to a population of women experiencing life-altering symptoms of urinary incontinence.
Advertisement
Advertisement
Trending on Drug Topics
1
EloraTZP Shows Greater Weight Loss, A1C Reduction Than Tirzepatide
2
FDA Approves Bepirovirsen Injection to Treat Chronic Hepatitis B
3
Pharmacist Roles, Risks in Guiding AI-Enabled Medical Device Use
4
Tailored Prevention, Care Necessary in Addressing Viral CAP
5